Teva Pharmaceutical Industries (TEVA -2.3%) has come out on the short end of an appeals court ruling on three patents covering weight-loss pill Contrave (naltrexone HCl and bupropion HCl).
In a 2-1 decision, the court upheld one patent that expires in 2030 but invalidated two others that expire in 2024 and 2025. Unfortunately for Teva, it is barred from selling a generic version until all three patents have expired.
Contrave, originally marketed by Takeda (licensed from Orexigen), is now sold by Nalproprion Pharmaceuticals, a joint venture between Pernix Therapeutics Holdings (OTCPK:PTXTQ) and certain institutional investors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.